糖尿病性末梢神経障害(Diabetic Peripheral Neuropathy)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Peripheral Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Diabetic Peripheral Neuropathy – Overview 7
Pipeline Products for Diabetic Peripheral Neuropathy – Comparative Analysis 8
Diabetic Peripheral Neuropathy – Therapeutics under Development by Companies 9
Diabetic Peripheral Neuropathy – Therapeutics under Investigation by Universities/Institutes 10
Diabetic Peripheral Neuropathy – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Diabetic Peripheral Neuropathy – Products under Development by Companies 13
Diabetic Peripheral Neuropathy – Products under Investigation by Universities/Institutes 14
Diabetic Peripheral Neuropathy – Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
BioChemics, Inc. 16
Cebix Incorporated 17
Pfizer Inc. 18
ViroMed Co., Ltd. 19
Diabetic Peripheral Neuropathy – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antimunocel – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ASP-8477 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
benfotiamine – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CBX-129801 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CNV-2197944 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
epalrestat – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PF-05089771 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VM-202 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Diabetic Peripheral Neuropathy – Recent Pipeline Updates 43
Diabetic Peripheral Neuropathy – Dormant Projects 46
Diabetic Peripheral Neuropathy – Discontinued Products 47
Diabetic Peripheral Neuropathy – Product Development Milestones 48
Featured News & Press Releases 48
Jun 09, 2012: Cebix’s Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50